Also found in: Medical, Wikipedia.
ALKSrilankan Airlines (ICAO code)
ALKAlkohol (German: alcohol)
ALKAnaplastic Lymphoma Kinase
ALKActivin Receptor-Like Kinase
ALKAlaska Air Group, Inc. (stock symbol)
ALKAutomated Limellar Keratoplasty (Surgical Procedure)
ALKAutomatisierte Liegenschaftskarte
ALKAnti-Lift Kit (Subaru suspension system)
ALKAllergologisk Laboratorium København (Allergological Laboratory of Copenhagen)
ALKAssociation Languedocienne de Kyudo (French; Japanese archery association)
References in periodicals archive ?
The encouraging results observed in a variety of patients previously treated with ALK inhibitors provides the basis for these applications.
In 2018, unit costs are expected to rise based on rising wages for both VA and ALK pilots and higher engine maintenance costs.
8-10) In addition to EGFR and ALK, several other oncogenic driver mutations with available, but not yet approved, targeted drugs are known.
Out of 25 cases, 22(88%) were ALCL ALK positive, 2(8%) were ALCL ALK negative and 1(4%) case was cutaneous ALCL.
First, the clinical trial accepted only patients with tumors positive for ALK rearrangement.
Assays like our Insight ALK Screen are important advancements in this evolving cancer landscape.
GenASIs Scan & Analysis offers clinicians a way to automatically perform genetic analysis on tissue samples, stained with the Abbott ALK[TM] probe kit, and identify the ALK gene rearrangement.
The ALK gene promotes lung cancer by encoding the production of ALK protein, an enzyme that is critical for the growth and development of cancer cells.
AS), and ALK Technologies, a specialist in mobile navigation software and transportation technology, announced on Thursday that the companies have entered into a license agreement under which ALK will use Tele Atlas maps and dynamic content in over 200 countries and territories worldwide.
A total of 43 samples were tested for ALK translocation and amplification utilizing the ALK RGQ RT-PCR Kit (Qiagen, Valencia, California).
We are excited by these data and the potential of lorlatinib to overcome resistance to ALK inhibitors, which remains a significant challenge for patients with ALK-positive NSCLC, said Mace Rothenberg, MD, senior vice president, head of development, Pfizer Oncology.